Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
HOME > BUSINESS
BUSINESS
- Qol Reaches Agreement for Approximately Half of Its Price Negotiations with Wholesalers
October 1, 2012
- Mochida Enters Generic Anticancer Drug Market with Hospira Products
October 1, 2012
- Osaka District Court Rules Against Takeda in Actos Patent Dispute with 8 Generic Drug Makers
October 1, 2012
- Novartis Obtains Approval for COPD Drug Seebri, Copromotion Planned with Eisai
October 1, 2012
- Daiichi Sankyo, AZ to Step Up Promotion for Nexium upon Lifting of Long-Term Prescription Ban
October 1, 2012
- Eisai Shifts Production Management Structure to Unit-Based Structure by Product Portfolio
October 1, 2012
- One-product, Two-brand Marketing Comes under Fire at CSIMC; Japanese Like Competition between Partners
October 1, 2012
- Nihon Chouzai Expects to Reach Agreement on Price Negotiations by End of September Despite Differences in Desired Prices
September 28, 2012
- Dilution-Free Formulation Approved for Zometa: Novartis
September 28, 2012
- GSK Ties Up with Tokyo University Venture for New Drug Candidate Exploration
September 28, 2012
- Eisai, Santen Conclude Option Agreement in Ophthalmologic Field
September 27, 2012
- Over 50,000 Patients Treated with Eli Lilly’s Forteo in 2 Years since Launch
September 27, 2012
- Kyowa Kirin Takes Full Control of South Korean Subsidiary
September 27, 2012
- GSK Files NDA for ICS/LABA Combination Drug for Asthma, COPD in Japan
September 27, 2012
- Santen to Establish New Sales and Marketing Subsidiary in China
September 27, 2012
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…